Tetramer analysis of EBV-CTL lines
| EBV-CTL lines (HLA type) . | B8 RAK . | B8 QAK . | A2 CLG . |
|---|---|---|---|
| Transgene expression . | |||
| No. 1 (HLA-A2,24;B8,65) | |||
| ΔCD34 | 8.9% | 4.3% | NT |
| iC.ΔCD34/IL-2 | 9.6% | 4.7% | NT |
| iC.ΔCD34/IL-15 | 12.2% | 1.8% | NT |
| No. 2 (HLA-A1,24;B8,18) | |||
| ΔCD34 | 0.7% | 9.3% | NT |
| iC.ΔCD34/IL-2 | 1.5% | 10.4% | NT |
| iC.ΔCD34/IL-15 | 0.7% | 31.4% | NT |
| No. 3 (HLA-A2;B8,57) | |||
| ΔCD34 | 2.3% | 26% | 9.3% |
| iC.ΔCD34/IL-2 | 2% | 3.6% | 13% |
| iC.ΔCD34/IL-15 | 1.4% | 1.3% | 6.2% |
| No. 4 (HLA-A1,2;B7,8) | |||
| ΔCD34 | 5.7% | NT | 0.4% |
| iC.ΔCD34/IL-2 | 5.8% | NT | 0.3% |
| iC.ΔCD34/IL-15 | 3.6% | NT | 0.4% |
| EBV-CTL lines (HLA type) . | B8 RAK . | B8 QAK . | A2 CLG . |
|---|---|---|---|
| Transgene expression . | |||
| No. 1 (HLA-A2,24;B8,65) | |||
| ΔCD34 | 8.9% | 4.3% | NT |
| iC.ΔCD34/IL-2 | 9.6% | 4.7% | NT |
| iC.ΔCD34/IL-15 | 12.2% | 1.8% | NT |
| No. 2 (HLA-A1,24;B8,18) | |||
| ΔCD34 | 0.7% | 9.3% | NT |
| iC.ΔCD34/IL-2 | 1.5% | 10.4% | NT |
| iC.ΔCD34/IL-15 | 0.7% | 31.4% | NT |
| No. 3 (HLA-A2;B8,57) | |||
| ΔCD34 | 2.3% | 26% | 9.3% |
| iC.ΔCD34/IL-2 | 2% | 3.6% | 13% |
| iC.ΔCD34/IL-15 | 1.4% | 1.3% | 6.2% |
| No. 4 (HLA-A1,2;B7,8) | |||
| ΔCD34 | 5.7% | NT | 0.4% |
| iC.ΔCD34/IL-2 | 5.8% | NT | 0.3% |
| iC.ΔCD34/IL-15 | 3.6% | NT | 0.4% |
The following HLA class I–restricted tetramers were used: HLA-A2 LMP2 epitope CLGGLLTML (CLG), HLA-B8 BZLF1 epitope RAKFQLL (RAK), HLA-B8 EBNA3A QAKWRLQTL (QAK).
ΔCD34 indicates CTLs transduced with the ΔCD34 control vector; iC.ΔCD34/IL-2v, CTLs transduced with the iC.ΔCD34/IL-2v; iC.ΔCD34/IL-15v, CTLs transduced with the iC.ΔCD34/IL-15v; and NT, not tested.